Quidel | QDEL - Cash And Equivalent


Quidel reported $140.4M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agilent USD 1.81B 49M Mar/2026
Avanos Medical USD 65.6M 24.2M Mar/2026
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Cerus USD 19.96M 4.29M Dec/2025
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
Haemonetics USD 245.44M 117.93M Mar/2026
Illumina USD 1.42B 368M Dec/2025
IQVIA Holdings USD 1.95B 33M Mar/2026
Merit Medical Systems USD 488.08M 41.68M Mar/2026
Mettler Toledo International USD 66.89M 2.18M Dec/2025
Myriad Genetics USD 124.4M 25.2M Mar/2026
Neogen USD 159.9M 14.56M Dec/2025
OraSure Technologies USD 176.96M 22.31M Mar/2026
Pacific Biosciences Of California USD 56.27M 223.23M Mar/2026
Quidel USD 140.4M 29.4M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
STAAR Surgical USD 153.15M 23M Dec/2025
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Waters USD 462M 125.83M Mar/2026